Gut microbial therapeutics are emerging as promising approaches for treating various health conditions. By manipulating the gut microbiome, researchers and clinicians are exploring new avenues for addressing digestive disorders, immune dysfunctions, and even mental health issues. Probiotics and prebiotics are two key components of gut microbial therapeutics. Probiotics, live microorganisms, can directly introduce beneficial bacteria into the gut, while prebiotics act as fuel for these beneficial bacteria. By restoring or modulating the gut microbiome, gut microbial therapeutics have the potential to improve overall health and well-being. However, more research is needed to fully understand the mechanisms and optimal applications of these therapies.
Title : Results from a cross-sectional observational study examining irritable bowel syndrome patients six months after finishing their participation in the ViIBS trial
Jacek Piatek, Calisia University, Poland
Title : Gut microbiome as a driver of healthy ageing
Thi Thu Hao Van, RMIT University, Australia
Title : Treating irritable bowel syndrome patients with a balanced multi-strain synbiotic–results from a multi-center, randomized, double-blind, placebo-controlled clinical trial (the ViIBS trial)
Henning Sommermeyer, Calisia University, Poland
Title : Molecular mechanisms underlying the anti-atherogenic actions of probiotics
Dipak P Ramji, Cardiff University, United Kingdom
Title : Global regulatory trends on the use of probiotics and prebiotics in foods and food supplements
David Pineda Ereno, DPE International Consulting, Belgium
Title : Biochemical profile and nutripotential glimpses of Terminalia arjuna bark extract
Suriyavathana Muthukrishnan, Periyar University, India